TIVC logo
Tivic Health Systems, Inc.(TIVC)
Closing price · checked 4:30 PM ETAbout this dataData status
$0.26▼-0.03 (-10.46%)
Extended:$0.49+0.23 (+90.14%)· 4:30 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →

More TIVC headlines

17 articles

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

accessnewswire.com·Mar 31

Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference

accessnewswire.com·Mar 27

Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

accessnewswire.com·Mar 26

Tivic Reports Full Year 2025 Results

accessnewswire.com·Mar 25

Tivic Health CEO Letter to Shareholders

accessnewswire.com·Mar 24

Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET

accessnewswire.com·Mar 20

Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma

accessnewswire.com·Mar 4

Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10

accessnewswire.com·Feb 18

Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting

accessnewswire.com·Jan 28

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

accessnewswire.com·Jan 26

Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference

accessnewswire.com·Jan 20

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

accessnewswire.com·Jan 12

Tivic Announces Special Webcast To Discuss Its Recent Acquisition of CDMO Assets - Highlighting Near-Term Strategic Potential and Immediate Contributions to Accelerated Drug Development Timelines

accessnewswire.com·Jan 8

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

accessnewswire.com·Dec 11

Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

accessnewswire.com·Nov 18

Tivic Reports Third Quarter 2025 Financial Results

accessnewswire.com·Nov 14

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

accessnewswire.com·Nov 13

Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.